Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral vs subcutaneous methotrexate in early rheumatoid arthritis
2020-000462-41Phase 4Active
- Sponsor
- Region Västerbotten
- Start
- Jan 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of methotrexate in rheumatoid arthritis (RA) (2 arms), sponsored by Region Västerbotten. Primary endpoints: Change in DAS28 over 12 months and DAS28 at each follow-up timepoint. Started Jan 2021; status: active.
02
Drugs
methotrexate
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2020-000462-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000462-41.